Back to results
US 8,889,366 B2Granted
Marker for graft failure and mortality
AssigneeB.R.A.H.M.S GmbH
InventorsJoachim Struck, Stephanus Johannes Bakker
Life of this patent
Estimating the term…
Abstract
Subject of the present invention is a biomarker for graft failure and/or mortality after organ transplantation. Procalcitonin was found to be a useful marker for the prediction or risk stratification for graft failure and/or mortality of a subject who has received an organ transplant and monitoring and therapy guidance of such subject.
Claims22
A method for at least one of prediction or risk stratification for at least one of graft failure or mortality of a subject that has received an organ transplant, and monitoring and therapy guidance of such a subject, comprising
- (a) detecting and quantitating, in a sample taken from said subject, procalcitonin, wherein the level of procalcitonin is detected and quantitated with a diagnostic assay, and
- (b) comparing the result to a predetermined statistically significant cut-off value range of between 0.0127 ng/mL and 0.1 ng/mL which range is correlated with the prediction or risk stratification for at least one of graft failure or mortality in a subject that has received an organ transplant;
- with the proviso that the sample is taken from the subject at least one week after transplantation;
- wherein
- when the level of procalcitonin in the sample is within the cut-off value range, the subject is predicted or stratified to have an increased risk for at least one of graft failure or mortality;
- and
- when the level of procalcitonin in the sample is outside of the cut-off value range, the subject is predicted or stratified to not have an increased risk for at least one of graft failure or mortality;
- and
- wherein, in each case, monitoring, therapy or both are indicated in accordance with the prediction or risk stratification or both of graft failure or mortality.
6 more elements
Dependencies are inferred from the claim text.